Householder Group Estate & Retirement Specialist LLC Decreases Stock Position in Johnson & Johnson (NYSE:JNJ)

Householder Group Estate & Retirement Specialist LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 89.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 612 shares of the company’s stock after selling 5,421 shares during the quarter. Householder Group Estate & Retirement Specialist LLC’s holdings in Johnson & Johnson were worth $88,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Pacer Advisors Inc. increased its stake in shares of Johnson & Johnson by 15.3% during the second quarter. Pacer Advisors Inc. now owns 240,605 shares of the company’s stock valued at $35,167,000 after buying an additional 31,908 shares during the period. Sei Investments Co. boosted its position in Johnson & Johnson by 10.7% during the second quarter. Sei Investments Co. now owns 1,126,658 shares of the company’s stock valued at $164,672,000 after purchasing an additional 109,205 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Johnson & Johnson by 31.8% during the second quarter. Thrivent Financial for Lutherans now owns 1,634,863 shares of the company’s stock valued at $238,951,000 after purchasing an additional 394,518 shares in the last quarter. Kiely Wealth Advisory Group Inc. boosted its position in Johnson & Johnson by 5.7% during the second quarter. Kiely Wealth Advisory Group Inc. now owns 1,847 shares of the company’s stock valued at $296,000 after purchasing an additional 99 shares in the last quarter. Finally, Summit Trail Advisors LLC boosted its position in Johnson & Johnson by 30.7% during the second quarter. Summit Trail Advisors LLC now owns 45,920 shares of the company’s stock valued at $6,712,000 after purchasing an additional 10,789 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday. Guggenheim raised their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Morgan Stanley raised their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Wells Fargo & Company raised their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $174.29.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Down 0.5 %

Shares of JNJ stock opened at $147.03 on Friday. The stock has a 50 day moving average of $148.51 and a 200 day moving average of $155.96. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $353.99 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.